 | Up a level |
Puoti, M; Foster, G; Wang, S; Mutimer, D; Gane, E; Moreno, C; Tsung Chang, T; Lee, SS; Marinho, R; Dufour, Jean-François; Pol, S; Hezode, C; Gordon, SC; Strasser, SI; Thuluvath, PJ; Liu, R; Pilot-Matias, T; Mensa, F (14 September 2017). High SVR Rates with 8 and 12 Weeks of Pangenotypic GlecapreviriPibrentasvir: PH2 Integrated Efficacy and Safety Analysis of Genotype 1-6 Patients without Cirrhosis. Swiss medical weekly, 147(Suppl 225), p. 20. EMH Schweizerischer Ärzteverlag
